Paper41345477
LIMD2 is associated with an exhausted CD8⁺ T cell state linked to ICI response in clear cell renal cell carcinoma.
Zhang J and 11 others. Sci Rep, 2025. Cited by 0 papers, by iCite.
Cite this record
ConductScience Library. LIMD2 is associated with an exhausted CD8⁺ T cell state linked to ICI response in clear cell renal cell carcinoma. Papers, record 41345477. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/41345477
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- LIMD2 is associated with an exhausted CD8⁺ T cell state linked to ICI response in clear cell renal cell carcinoma.
- PubMed
Topics10
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Carcinoma, Renal Cell | Major topic |
| CD8-Positive T-Lymphocytes | Major topic |
| Kidney Neoplasms | Major topic |
| Immune Checkpoint Inhibitors | Major topic |
| LIM Domain Proteins | Major topic |
| Humans | |
| Lymphocytes, Tumor-Infiltrating | |
| Single-Cell Analysis | |
| Gene Expression Regulation, Neoplastic | |
| Male |
Source PubMed
Grants5
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by |
|---|---|---|---|---|
| 82260791 | National Natural Science Foundation of China | PubMed | ||
| 32560174 | National Natural Science Foundation of China | PubMed | ||
| 2025AFD770 | Natural Science Foundation of Hubei Provincial | PubMed | ||
| 2024E02058 | Science and Technology Assistance Program for Xinjiang | PubMed | ||
| 2023D01C124 | Natural Science Foundation of Xinjiang Uygur Autonomous Region | PubMed |
Source PubMed
References49
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 19097774 | New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). | Eur J Cancer | 2009 | https://conductscience.org/library/papers/19097774 | PubMed |
| 2 | 25348003 | Metastasis is regulated via microRNA-200/ZEB1 axis control of tumour cell PD-L1 expression and intratumoral immunosuppression. | Nat Commun | 2014 | https://conductscience.org/library/papers/25348003 | PubMed |
| 3 | 24590809 | LIMD2 is a small LIM-only protein overexpressed in metastatic lesions that regulates cell motility and tumor progression by directly binding to and activating the integrin-linked kinase. | Cancer Res | 2014 | https://conductscience.org/library/papers/24590809 | PubMed |
| 4 | 27538576 | Tumor Mutational Load and Immune Parameters across Metastatic Renal Cell Carcinoma Risk Groups. | Cancer Immunol Res | 2016 | https://conductscience.org/library/papers/27538576 | PubMed |
| 5 | 33711273 | Progressive immune dysfunction with advancing disease stage in renal cell carcinoma. | Cancer Cell | 2021 | https://conductscience.org/library/papers/33711273 | PubMed |
| 6 | 34354714 | CD8+ T Cell Exhaustion in Cancer. | Front Immunol | 2021 | https://conductscience.org/library/papers/34354714 | PubMed |
| 7 | 31031094 | Cholesterol Induces CD8+ T Cell Exhaustion in the Tumor Microenvironment. | Cell Metab | 2019 | https://conductscience.org/library/papers/31031094 | PubMed |
| 8 | 34580473 | Enhancing immunotherapy in cancer by targeting emerging immunomodulatory pathways. | Nat Rev Clin Oncol | 2022 | https://conductscience.org/library/papers/34580473 | PubMed |
| 9 | 33711272 | Tumor and immune reprogramming during immunotherapy in advanced renal cell carcinoma. | Cancer Cell | 2021 | https://conductscience.org/library/papers/33711272 | PubMed |
| 10 | 27570942 | Radiotherapy combination opportunities leveraging immunity for the next oncology practice. | CA Cancer J Clin | 2017 | https://conductscience.org/library/papers/27570942 | PubMed |
| 11 | 34597799 | ESMO Clinical Practice Guideline update on the use of immunotherapy in early stage and advanced renal cell carcinoma. | Ann Oncol | 2021 | https://conductscience.org/library/papers/34597799 | PubMed |
| 12 | 36793322 | Oxygen-carrying nanoplatform to reprogram tumor immunosuppressive microenvironment and enhance photothermal-immunotherapy. | Mater Today Bio | 2023 | https://conductscience.org/library/papers/36793322 | PubMed |
| 13 | 34715028 | Determinants of anti-PD-1 response and resistance in clear cell renal cell carcinoma. | Cancer Cell | 2021 | https://conductscience.org/library/papers/34715028 | PubMed |
| 14 | 30096699 | Role of radiotherapy in improving activity of immune-modulating drugs in advanced renal cancer: Biological rationale and clinical evidences. | Cancer Treat Rev | 2018 | https://conductscience.org/library/papers/30096699 | PubMed |
| 15 | 33658305 | Molecular correlates of response to nivolumab at baseline and on treatment in patients with RCC. | J Immunother Cancer | 2021 | https://conductscience.org/library/papers/33658305 | PubMed |
| 16 | 31591533 | Precursor exhausted T cells: key to successful immunotherapy? | Nat Rev Immunol | 2020 | https://conductscience.org/library/papers/31591533 | PubMed |
| 17 | 32951909 | Preoperative immunotherapy for resectable hepatocellular carcinoma: Toward a paradigm shift? | J Hepatol | 2020 | https://conductscience.org/library/papers/32951909 | PubMed |
| 18 | 30676822 | CD8 T Cell Exhaustion During Chronic Viral Infection and Cancer. | Annu Rev Immunol | 2019 | https://conductscience.org/library/papers/30676822 | PubMed |
| 19 | 38854736 | Immunotherapy and stereotactic body radiotherapy for older patients with non-metastatic renal cancer unfit for surgery or decline nephrectomy: practical proposal by the International Geriatric Radiotherapy Group. | Front Oncol | 2024 | https://conductscience.org/library/papers/38854736 | PubMed |
| 20 | 25809635 | PD-1 alters T-cell metabolic reprogramming by inhibiting glycolysis and promoting lipolysis and fatty acid oxidation. | Nat Commun | 2015 | https://conductscience.org/library/papers/25809635 | PubMed |
Genes2
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| CD8A | 925 | PubTator's text mining | https://conductscience.org/library/genes/925 | NCBI Gene |
| LIMD2 | 80774 | PubTator's text mining | https://conductscience.org/library/genes/80774 | NCBI Gene |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Comments and corrections
- Cited by
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/41345477
GET https://conductscience.org/api/papers/v1/41345477/references?page=2